Abstract
INTRODUCTION
Severe acute pancreatitis (SAP) is a common surgical acute abdominal disease and can lead to the early death of patients because of associated systemic inflammatory response syndrome and multiple organ dysfunction syndrome [1] . One severe complication is often intestinal barrier damage. This permits great quantities of gut bacteria and endotoxin to enter the blood and lymphatic circulations, and eventually whole internal organs [2] . Also, the body's mononuclear macrophage system is activated, which leads to release of large quantities of tumor necrosis factor (TNF), interferons, interleukins, and other inflammatory factors to trigger cascade of inflammatory events that further cause tissue damage [3, 4] . Secreted phospholipase A2 (sPLA2), the main phos pholipase A subtype, is a damage factor whose function depends on intracellular calcium ion concentration. Under the stimulus of excessive sPLA2 expression, large amounts of inflammatory factors cause the degradation of cell surface active substances and hydrolyze biologic membranes to aggravate lecithin damage in organs and tissues [5, 6] . The efficacy of the Chinese medicine Qingyi decoction (QYT) has been demonstrated through clinical practice and animal experiments for years; QYT is an effective prescription for the treatment of acute pancreatitis [6] . It is generally well tolerated by patients, and induces purgation, promotes blood circulation, eliminates blood stasis, and reduces inflammation. It can also directly neutralize endotoxins and protect the intestinal barrier. In our previous study on the intervening role of QYT in patients following acute pancreatitis, it was shown that QYT administration reduced lung injury by decreasing the transcription of sPLA2, thereby protecting pulmo nary function [6] . Dexamethasone (DEX) is a glucocorticoid with several beneficial functions including anti-inflammatory activity, microcirculation promotion, and oxygen free radical scavenging. Verapamil (VER) can effectively reduce tissue damage, especially intestinal damage, by reducing intracellular calcium ion concentration which plays a decisive role in sPLA2 activation [7] . VER is a commonly used calcium blocker. Considering its inhibitory effect on sPLA2, VER may be used to protect against intestinal tissue and pancreatic injuries during SAP.
The present study aimed to examine the role of sPLA2 in a rat model of SAPinduced intestinal barrier injury and the intervening roles of QYT and VER.
MATERIALS AND METHODS

Animals and grouping
Fifty cleangrade healthy male SpragueDawley rats (180220 g, age: 8 wk) were purchased from the specific-pathogen-free Animal Center of Dalian Medical University (Dalian, China). The animals were randomly divided into five groups (n = 10 per group): controls, untreated SAP, and SAP treated with QYT (Chinese Medicine Preparations Division, First Affiliated Hospital of Dalian Medical University, Dalian, China, Supplementary 1), DEX (Ling Rui Pharmaceutical, Zhengzhou, China), or VER (Harvest Pharmaceutical, Shanghai, China). This study was carried out in strict accordance with the recommendations in the European Union Animal Management Practices (1986). The animal use protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Dalian Medical University (Dalian, China).
Model preparation
The SAP intestinal barrier damage model was established using bile pancreatic duct retrograde injection of 1.5% absorbance was read at 340 nm wavelength for the value of A1. The mixture was placed in a water bath (37 ℃) for 10 min, and then the absorbance at 340 nm was read again for the A2 value. The DAO activity (U/L) = {[A1 × A2]/[A2 × cuvette diameter (cm) × 6.3 × NADH mmol extinction coefficient] × [reaction liquid volume (µL)/sample volume (µL)]} × 1000.
Detection of intestinal epithelial cell apoptosis
A terminal deoxynucleotidyl transferasemediated dUTP nickend labeling assay kit (Keygen, Nanjing, China) was used to detect apoptosis of epithelial cells in paraffin-embedded intestinal tissues according to the manufacturer's instructions. Under high magnification (200 ×), five randomly selected areas were observed. The apoptosis index (AI) was calculated as the percentage of fluorescein isothiocyanate-positive cells out of 500 intestinal epithelial cells.
Quantitative PCR assessment of intestinal sPLA2 mRNA expression
Total RNA was extracted from intestinal tissue using RNAisoPlus (Takara Bio Inc., Otsu, Shiga, Japan) according to the manufacturer's instructions. Briefly, 1 mL of RNAisoPlus was added to 50 mg of tissue and homogenized on ice. Then 200 µL of chloroform was added and the mixture centrifuged before the supernatant was collected. Isopropyl alcohol was used to precipitate the RNA from the chloroform. Precipitated RNA was dissolved in RNasefree water and its quality measured using an ultraviolet spectrophotometer. The observed values of A260/ A280 ranged between 1.8 and 2.0. The routine PCR condition included 30 cycles at an annealing temperature of 60 ℃ for 30 s. Primers (Takara) were as follows: sPLA2, 5′-GTGGCAGGATCCCCCAAGG-3′ (upstream), 5′-GCAACTGGGCGTGTTCCCTCTGCA-3′ (downstream), product length, 283 bp; and βactin, 5′-GGAGTCCTGTGGCATCCACG-3′ (upstream), 5′-CTAGAAGCATTTGCGGTGGA-3′ (downstream), product length, 531 bp. An ultraviolet imaging system (Protein Simple; Alphalmade HP, Santa Clara, CA, United States) was used to read the PCR products after agarose gel electrophoresis. Intestinal tissue sPLA2 mRNA expression level was estimated as the ratio of intestinal sPLA2 mRNA gray value to its corresponding internal control (βactin) grey value.
Western blotting for intestinal tissue sPLA2 protein expression
Total protein was extracted using 1 mL of RIPA lysis buffer supplemented with 1 µL protease inhibitor solution, 5 µL PMSF and 10 µL phosphatase inhibitor (all purchased from Keygen, Nanjing, China) for every 100 mg of intestinal tissue; protein (100 µg) from each sample was separated on SDS-PAGE and transferred onto a nitrocellulose membrane. Sections of the membrane were cut according to the estimated deoxycholic acid sodium salt (Baier Di Biotechnology, Beijing, China). The rats were subject to preoperative fasting of 12 h with free access to drinking water, and administered 10% chloral hydrate anesthesia (ip, 3 mL/kg) prior to operation. Under sterile conditions, the needle of a 1 mL syringe was inserted into the major duodenal papilla of the rat and 1.5% deoxycholic acid sodium salt (1 mL/kg dose, speed of 0.1 mL/min) was injected through the bile pancreatic duct into the pancreas. The control group only had their pancreas marginally rotated to avoid any incidence of mild acute pancreatitis that could arise following the injection of the solvent (water) used to dissolve the salt. The very short time (24 h) required for the manifestation of chemically induced SAP would not permit complete resolution of such mild acute pancreatitis in the control rats, which would in turn compromise the principal clinical differences between the control and the SAP groups. The DEX group (10 mg/kg body weight/dose, 5 mg/mL concentration) and VER group (1.25 mg/kg body weight/dose, 2.5 mg/mL concentration) were given their respective drugs intravenously immediately, 6 and 12 h postoperation. The QYT group, however, was orally treated with QYT (10 mL/kg body weight/ dose) 0.5 h before the induction of SAP (to permit enough time for the absorption of the traditional drug into the blood), and then 6 and 12 h postoperation. At 24 h postoperation, animals were anesthetized and abdominal aortic blood was taken for serum collection and storage at 80 ℃ until use. The pancreas and intestinal tissues were harvested, and part of each was either immediately stored at 80 ℃ or fixed in neutral phosphate formaldehyde.
Pathologic observation
Pathologic observations were made under an optical microscope (Leica DMIRB; Leica, Solms, Germany). Pancreas and intestinal tissues previously fixed in neutral phosphate formaldehyde were paraffin embedded and sectioned (2 µm serial sectioning) for pathologic morphology observation after routine hematoxylin and eosin staining.
Serum amylase, TNF-α, and diamine oxidase measurement
Serum amylase content was determined using a fully automatic biochemical analyzer (Abbott Laboratories, ML, United States) from 50 µL of rat serum that was diluted six times with MilliQ (Millipore Corp, Billerica, MA, United States) water before acquisition.
Serum TNFα level was determined using an enzyme linked immunosorbent assay kit (Lengton Company, Shanghai, China) according to the manufacturer's instructions.
For diamine oxidase (DAO) detection, 80 µL of serum was added to 800 µL of detection reagent (Tris-HCl, reduced coenzyme, glutamate dehydrogenase, 1. gentle rocking. After incubation, the membrane was rinsed three times and incubated in HRP-conjugated secondary antibody (1:10000) at 37 ℃ with gentle rocking for 1 h, then rinsed three times and bands visualized using enhanced chemiluminescence followed by film exposure. Band intensities were analyzed using ImageJ software, version 1.35d (National Institutes of Health, Bethesda, MD, United States).
Statistical analysis
Statistical analysis was conducted using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, United States). All data are reported as mean ± SD, and analysis of variance was used for comparisons among the groups. A P < 0.05 was considered statistically significant. The Pearson productmoment correlation was used for correlation analysis.
RESULTS
Pancreatic and intestinal tissue histopathology
Substantial pathologic changes were observed in the pancreatic and intestinal tissues from each group of rats except the control group, where mucosa lobular structures did not exhibit edema or bleeding. Other features observed in the disease groups included blurred SAP pancreas lobular structures, large numbers of inflammatory cell infiltration, extensive hemorrhaging, and intestinal epithelial cell necrosis of > 50%. However, the pathologic damage in QYT, DEX, and VER groups was greatly reduced compared to the SAP group. The QYT and VER groups exhibited intestinal mucosal epithelial cell swelling, generally of normal morphology, whereas the DEX group, in addition to cell swelling deformation, showed varying degrees of inflammatory cell infiltration. Their pancreatic lobule structures were clear with only a small amount of edema, hemorrhage, and inflammatory cell invasion. Necrotic areas were the smallest compared to the DEX and SAP groups (Figure 1 ).
Serum levels
Compared with the control group, serum AMY levels in the SAP rats significantly increased (P < 0.01) ( Table  1) . However, serum AMY levels in the treated (QYT, DEX or VER) groups were significantly lower compared with the SAP group (Ps < 0.05). Furthermore, serum TNFα levels were significantly elevated in the SAP group compared to controls (P < 0.01). The serum TNFα levels significantly decreased in the SAP rats following QYT, DEX, or VER intervention (Ps < 0.05). Serum DAO levels in the SAP group were significantly higher than controls (P < 0.01). Compared with the SAP group, levels of serum DAO in the QYT, DEX and VER groups decreased significantly (Ps < 0.05).
Intestinal epithelial cell apoptosis
The intestinal epithelial cell AI in the SAP group was significantly higher compared with controls (P < 0.01). However, compared with the SAP group, the AIs of the QYT, DEX, or VER groups were significantly lower (Ps < 0.05). The AI of the QYT group was the most reduced among the treated cohort (Table 1 ) (Figure 2 ). 
J I sPLA2 mRNA expression in intestinal tissue
Compared with the control group, intestinal tissue sPLA2 mRNA expression in the SAP group was significantly higher (P < 0.01) (Figure 3 ). The sPLA2 mRNA expression level in the QYT, DEX, and VER groups, however, were significantly lower compared with the SAP group (Ps < 0.05).
sPLA2 protein expression in intestinal tissue and correlation analysis
The expression of sPLA2 protein in the intestinal tissue of the SAP group was significantly higher compared with the control group (P < 0.01) (Figure 4 ). Upon intervention with QYT, DEX, or VER in SAP rats, the protein level decreased significantly (Ps < 0.05). The inhibition of the sPLA2 protein expression was superior in the QYT treatment group. Nonetheless, the intestinal expression of sPLA2 protein in the QYT, DEX, and VER groups was significantly higher compared with controls (Ps < 0.05). The protein expression level of sPLA2 positively correlated with serum TNFα and DAO levels in the SAP rats (Ps < 0.05) ( Table 2) .
DISCUSSION
sPLA2 is widely present in mammalian tissues and cells, and functions to rebuild phospholipids, transmit signals in cell physiologic processes, and plays an important role in some diseases, such as SAP [7] . Overexpression of sPLA2 promotes a large release of arachidonic acid, prostaglandin, plateletactivating factors, and other bioactive substances [810] . Overexpression of sPLA2 is mainly stimulated by a large number of inflammatory mediators, and it is an important factor in intestinal
3542
March 28, 2015|Volume 21|Issue 12| WJG|www.wjgnet.com 
D C B A E
Zhang JW et al . Qingyi decoction and intestinal barrier injury ischemiareperfusion injury [11, 12] . sPLA2 can degrade phospholipid components of cell membranes, and thus directly damage the intestinal mucosa. It can also indirectly cause ischemiareperfusion injury and deregulate the inflammatory cytokine network, and thus attack the intestinal barrier in the development and progression of SAP [1315] . The overall consequences include decreased intestinal peristalsis and intestinal epithelial cell apoptosis and necrosis [1618] . These activities may promote the multiplication of intestinal bacteria and their translocation into the blood, which can cause gut origin sepsis and endotoxemia [19] [20] [21] . Destruction of the intestinal mucosa mechanical barrier also results in the release of a large amount of diamine oxidase enzymes and active substances [2224] . Wilmore et al [25] first proposed that intestinal barrier injury may lead to systemic inflammatory response syndrome and multiple organ dysfunction syndrome [2630] . Therefore, the study of the role of sPLA2 in the pathogenesis of intestinal barrier damage in SAP is of great signi ficance.
We found that SAP successfully developed in the rats after 24 h of disease induction, characterized by pancreatic and intestinal tissue injury, and pathologic changes. The serum levels of AMY, TNF-α, and DAO significantly increased in the SAP group compared with either the controls or any of the treated groups. 
Intestinal epithelial cell apoptosis index and sPLA2 expression at both the mRNA and protein levels were also significantly increased in the SAP group. Additionally, the expression level of sPLA2 positively and significantly correlated with serum TNF-α and DAO levels. The extent of damage to the intestinal barrier positively correlated with intestinal sPLA expression level, thus suggesting the involvement of sPLA2 in the process of intestinal barrier damage in SAP.
QYT, DEX and VER demonstrated the potential to reduce damage to the pancreatic and intestinal tissues. These drugs also decreased serum AMY, TNF-α, and DAO levels, the intestinal epithelial cell AI, and the expression of sPLA2 mRNA and protein. However, the interventional effect of QYT and VER were better. Thus, administration of QYT may help reduce symptoms of intestinal paralysis [31] . QYT is also suggested to promote the inhibition of intestinal phospholipase overexpression, the release of inflammatory mediators and toxic substances, and reduce the proliferation of intestinal bacteria and the effect of their endotoxin, which when in the blood, triggers systemic inflammation [9, 26] . However the precise mechanism by which QYT protects intestinal damage is yet to be comprehensively elucidated.
DEX is commonly used clinically as an antiinfla mmatory agent as it inhibits inflammation and infla mmation promoters, decreases vascular permeability, and antagonizes phospholipase A2induced release of plateletactivating factor to ease inflammation and reduce tissue injury [3234] . This study used DEX as a reference drug to compare the therapeutic effects of QYT and VER on intestinal barrier damage during SAP progression in rats. Both experimental drugs effectively reduced the expression of sPLA2 at the transcriptional and translational levels as compared to the reference drug, and offered superior therapeutic effect against the extent of intestinal barrier damage. Preliminary results (data not shown) indicated that sPLA2 expression was significantly higher in intestinal mucosa than in the lung tissue of SAP rats. Thus, suggesting that the role of sPLA2 in intestinal barrier injury deserves attention.
Six hours postoperation and drug administration, the vitality of the rats in a descending order was in the DEX, QYT, and VER groups. However, 24 h postoperation, vitality was superior and disease progression was also gentler in the QYT and VER groups compared with the DEX group. The onset of QYT therapeutic effect, although slower, persisted longer compared with DEX. QYT has been widely used in clinical settings, particularly for the treatment of SAP and lung injury [35, 36] . Acute pancreatitis is currently diagnosed based on clinical staging, disease evolution, and other characteristics. Its treatment may be greatly enhanced if Western orthodox medicine is combined with traditional medicinal preparations, such as QYT, for a synergistic therapeutic effect, and also to ameliorate some of the commonly associated complications, including intestinal barrier injury.
COMMENTS
Background
Severe acute pancreatitis (SAP) can lead to the early death of patients because of associated systemic inflammatory response syndrome and multiple organ dysfunction syndromes. However, its pathogenesis has not been fully elucidated, which has impaired the development and availability of specific clinical treatments to date.
Research frontiers
It is currently recognized that intestinal barrier injury is the initiating factor for SAP-associated multiple organ failure.
Innovations and breakthroughs
The therapeutic function of the traditional Chinese medicine, Qingyi decoction, was comparable to the Western orthodox drug verapamil in a rat model of SAP. Qingyi decoction, although slower in onset of action, effectively inhibited the overexpression of secreted phospholipase A2 (sPLA2), which is known to play an essential pathologic role in the development of intestinal barrier injury, a common complication in SAP.
Applications
The intestinal transcription and protein expression levels of sPLA2 positively correlated with the serum levels of proinflammatory factors tumor necrosis factor-α and diamine oxidase, and therefore, may be of diagnostic and/or prognostic significance in SAP disease.
Peer-review
SAP remains a serious clinical problem with significant morbidity and mortality. Studies suggest that loss of the gut barrier function is instrumental in the local and systemic infectious complications associated with a severe course of the disease. Improvement of intestinal barrier function may be a useful strategy to alleviate the severity and possibility of infectious complication in SAP. This study explored the involvement of sPLA2 in intestinal barrier injury in SAP, and the intervening role of Qingyi decoction and verapamil in comparison with dexamethasone as a reference treatment. Qingyi decoction is a traditional Chinese prescription in treatment of SAP. This study is interesting and important to the field. 
COMMENTS
